Hypernatremia Treatment & Management
- Author: Ivo Lukitsch, MD; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
The goals of management in hypernatremia are as follows :
- Recognition of the symptoms, when present
- Identification of the underlying cause(s)
- Correction of volume disturbances
- Correction of hypertonicity
Correcting the hypertonicity requires a careful decrease in serum sodium and plasma osmolality with the replacement of free water, either orally or parenterally. The rate of sodium correction depends on how acutely the hypernatremia developed and on the severity of symptoms.
Acute symptomatic hypernatremia, defined as hypernatremia occurring in a documented period of less than 24 hours, should be corrected rapidly. Chronic hypernatremia (>48 h), however, should be corrected more slowly due to the risks of brain edema during treatment. The brain adjusts to and mitigates chronic hypernatremia by increasing the intracellular content of organic osmolytes. If extracellular tonicity is rapidly decreased, water will move into the brain cells, producing cerebral edema, which may lead to herniation, permanent neurologic deficits, and myelinolysis.
Treatment recommendations for symptomatic hypernatremia
Recommendations are as follows:
Establish documented onset (acute, < 24 h; chronic, >24h)
In acute hypernatremia, correct the serum sodium at an initial rate of 2-3 mEq/L/h (for 2-3 h) (maximum total, 12 mEq/L/d).
Measure serum and urine electrolytes every 1-2 hours
Perform serial neurologic examinations and decrease the rate of correction with improvement in symptoms
Chronic hypernatremia with no or mild symptoms should be corrected at a rate not to exceed 0.5 mEq/L/h and a total of 8-10 mEq/d (eg, 160 mEq/L to 152 mEq/L in 24 h).
If a volume deficit and hypernatremia are present, intravascular volume should be restored with isotonic sodium chloride prior to free-water administration.
Estimation of the replacement fluid
Total body water (TBW) refers to the lean body weight of the patient (percentage of TBW decreases in morbidly obese patients). The TBW deficit in the hyperosmolar patient that needs to be replaced can be roughly estimated using the formula following formula:
TBW deficit = correction factor x premorbid weight x (1 - 140/Na+)
Ongoing losses (insensible, renal) need to be added.
However, the formulae below, by Adrogué–Madias, are preferred over the conventional equation for water deficit, because the older equation underestimates the deficit in patients with hypotonic fluid loss and is not useful in situations in which sodium and potassium must be used in the infusate. Formulas used to manage hypernatremia are outlined below.
Equation 1: TBW = weight (kg) x correction factor
Correction factors are as follows:
Nonelderly men: 0.6
Nonelderly women: 0.5
Elderly men: 0.5
Elderly women: 0.45
Equation 2: Change in serum Na+ = (infusate Na+ - serum Na+) ÷ (TBW + 1)
Equation 3: Change in serum Na+ = ([infusate Na+ + infusate K+] – serum Na+) ÷ (TBW + 1)
Equation 2 allows for the estimation of 1 L of any infusate on serum Na+ concentration. Equation 3 allows for the estimation of 1 L of any infusate containing Na+ and K+ on serum Na+.
Common infusates and their Na+ contents include the following:
5% dextrose in water (D 5 W): 0 mmol/L
0.2% sodium chloride in 5% dextrose in water (D 5 2NS): 34 mmol/L
0.45% sodium chloride in water (0.45NS): 77 mmol/L
Ringer's lactate solution: 130 mmol/L
0.9% sodium chloride in water (0.9NS): 154 mmol/L
An example of the use of the above calculations is as follows: An obtunded 80-year-old man is brought to the emergency room with dry mucous membranes, fever, tachypnea, and a blood pressure of 134/75 mm Hg. His serum sodium concentration is 165 mmol/L. He weighs 70 kg. This man is found to have hypernatremia due to insensible water loss.
The man's TBW is calculated by the following:
(0.5 x 70) = 35 L
To reduce the man's serum sodium, D5 W will be used. Thus, the retention of 1 L of D5 W will reduce his serum sodium by (0 - 165) ÷ (35 + 1) = -4.6 mmol. The goal is to reduce his serum sodium by no more than 10 mmol/L in a 24-hour period. Thus, (10 ÷ 4.6) = 2.17 L of solution is required. About 1-1.5 L will be added for obligatory water loss to make a total of up to 3.67 L of D5 W over 24 hours, or 153 cc/h.
A clinically important study by Lindner and colleagues found that all the above formulae correlated significantly with measured changes in serum sodium in the patient cohort as a whole, but the individual variations were extreme. Thus, although the above formulae can guide therapy, serial measurements of serum sodium are prudent. That finding is no surprise, considering that interindividual variables make it difficult to precisely estimate the individual TBW and its distribution in different body compartments. For example, the degree to which interindividual differences in body fat percentage affect TBW is very large.
Other treatment considerations
If hypernatremia is accompanied by hyperglycemia with diabetes, take care when using a glucose-containing replacement fluid. However, the appropriate use of insulin will help during correction.
In hypervolemic and hypernatremic patients in the ICU who have an impaired renal excretion of sodium and potassium (eg, after renal failure) an addition of a loop diuretic to free water boluses increases renal sodium excretion. Fluid loss during loop diuretic therapy must be restored with the administration of fluid that is hypotonic to the urine.
Hypernatremia in the setting of volume overload (eg, heart failure and pulmonary edema) may require dialysis for correction.
Although water can be replaced by oral and parenteral routes, an obtunded patient with a large free water deficit likely requires parenteral treatment. If the deficit is small and the patient is alert and oriented, oral correction may be preferred.
Once hypernatremia is corrected, efforts are directed at treating the underlying cause of the condition. Such efforts may include free access to water and better control of diabetes mellitus. In addition, correction of hypokalemia and hypercalcemia as etiologies for nephrogenic diabetes insipidus may be required. Vasopressin (AVP, DDAVP) should be used for the treatment of central diabetes insipidus.
Surgical treatment may be required in the setting of severe central nervous system trauma and associated central diabetes insipidus.
Consultations include the following:
Neurosurgeon (head trauma)
Endocrinologist (diabetes insipidus or diabetes mellitus)
Nephrologist (nephrogenic etiologies for hypernatremia)
Diet should be altered as applicable to diabetes mellitus and need for increased water intake during increased insensible loss. A low-sodium diet will reduce oral solute intake and therefore diminish renal water loss.
Activity alterations are applicable only as related to free access to water.
Muhsin SA, Mount DB. Diagnosis and treatment of hypernatremia. Best Pract Res Clin Endocrinol Metab. 2016 Mar. 30 (2):189-203. [Medline].
Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med. 2000 May 18. 342(20):1493-9. [Medline].
Verbalis JG. Disorders of Water Balance. In:. Skorecki K, Chertow GM, Marsden PA, Yu ASL, Taal MW, eds. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Elsevier; 2016. 460-510.
Chumlea WC, Guo SS, Zeller CM, et al. Total body water data for white adults 18 to 64 years of age: the Fels Longitudinal Study. Kidney Int. 1999 Jul. 56(1):244-52. [Medline].
Bhave G, Neilson EG. Body fluid dynamics: back to the future. J Am Soc Nephrol. 2011 Dec. 22(12):2166-81. [Medline].
Sterns HR. Renal function and disorders of water and sodium balance. ACP Medicine: A Publication of the American College of Physicians. New York, NY: WebMD; 2005. 10.1-10.19.
Boone M, Deen PM. Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch. 2008 Sep. 456(6):1005-24. [Medline]. [Full Text].
Loh JA, Verbalis JG. Disorders of water and salt metabolism associated with pituitary disease. Endocrinol Metab Clin North Am. 2008 Mar. 37(1):213-34, x. [Medline].
Thornton SN. Thirst and hydration: Physiology and consequences of dysfunction. Physiol Behav. 2010. 100:15-20. [Medline].
Kumar S, Berl T. Sodium. Lancet. 1998 Jul 18. 352(9123):220-8. [Medline].
Darmon M, Timsit JF, Francais A, et al. Association between hypernatraemia acquired in the ICU and mortality: a cohort study. Nephrol Dial Transplant. 2010 Feb 17. [Medline].
Lindner G, Funk GC, Schwarz C, et al. Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis. Dec 2007. 50(6):952-7. [Medline].
Stelfox HT, Ahmed SB, Khandwala F, et al. The epidemiology of intensive care unit acquired hyponatremia and hypernatremia in medical-surgical intensive care units. Crit Care. 2008 Dec 18. 12(6):R162. [Medline]. [Full Text].
Funk GC, Lindner G, Druml W, et al. Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. 2010 Feb. 36(2):304-11. [Medline].
Ates I, Özkayar N, Toprak G, Yılmaz N, Dede F. Factors associated with mortality in patients presenting to the emergency department with severe hypernatremia. Intern Emerg Med. 2016 Apr. 11 (3):451-9. [Medline].
Kumar AB, Shi Y, Shotwell MS, Richards J, Ehrenfeld JM. Hypernatremia is a Significant Risk Factor for Acute Kidney Injury After Subarachnoid Hemorrhage: A Retrospective Analysis. Neurocrit Care. 2014 Sep 18. [Medline].
VAN DE Louw A, Shaffer C, Schaefer E. Early intensive care unit-acquired hypernatremia in severe sepsis patients receiving 0.9% saline fluid resuscitation. Acta Anaesthesiol Scand. 2014 Sep. 58(8):1007-14. [Medline].
Leung AA, McAlister FA, Finlayson SR, Bates DW. Preoperative hypernatremia predicts increased perioperative morbidity and mortality. Am J Med. 2013 Oct. 126(10):877-86. [Medline].
Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003 Nov. 337(1-2):169-72. [Medline].
Lavagno C, Camozzi P, Renzi S, Lava SA, Simonetti GD, Bianchetti MG, et al. Breastfeeding-Associated Hypernatremia: A Systematic Review of the Literature. J Hum Lact. 2016 Feb. 32 (1):67-74. [Medline].
Herrod PJ, Awad S, Redfern A, et al. Hypo- and hypernatraemia in surgical patients: is there room for improvement?. World J Surg. 2010 Mar. 34(3):495-9. [Medline].
Chassagne P, Druesne L, Capet C, et al. Clinical presentation of hypernatremia in elderly patients: a case control study. J Am Geriatr Soc. Aug 2006. 54(8):1225-30. [Medline].
Palevsky PM. Hypernatremia. Semin Nephrol. 1998 Jan. 18(1):20-30. [Medline].
Hoefer D, Ruttmann-Ulmer E, Smits JM, et al. Donor hypo- and hypernatremia are predictors for increased 1-year mortality after cardiac transplantation. Transpl Int. 2009 Dec 14. [Medline].
Hiyama TY, Matsuda S, Fujikawa A, et al. Autoimmunity to the sodium-level sensor in the brain causes essential hypernatremia. Neuron. 2010 May 27. 66(4):508-22. [Medline].
Lin JJ, Lin KL, Hsia SH, et al. Combined central diabetes insipidus and cerebral salt wasting syndrome in children. Pediatr Neurol. 2009 Feb. 40(2):84-7. [Medline].
Bockenhauer D, van't Hoff W, Dattani M, et al. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol. 2010. 116(4):p23-9. [Medline].
Mavrakis AN, Tritos NA. Diabetes insipidus with deficient thirst: report of a patient and review of the literature. Am J Kidney Dis. 2008 May. 51(5):851-9. [Medline].
Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am. 1997 May. 81(3):585-609. [Medline].
Lindner G, Schwarz C, Kneidinger N, et al. Can we really predict the change in serum sodium levels? An analysis of currently proposed formulae in hypernatraemic patients. Nephrol Dial Transplant. 2008 Nov. 23(11):3501-8. [Medline].
Lindner G, Funk GC. Hypernatremia in critically ill patients. J Crit Care. 2012 Jul 2. [Medline].
Lindner G, Schwarz C, Funk GC. Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients. Nephrol Dial Transplant. 2012 Mar. 27(3):962-7. [Medline].
|Characteristics of hypernatremia||Symptoms related to the characteristics of hypernatremia|
|Cognitive dysfunction and symptoms associated with neuronal cell shrinkage||Lethargy, obtundation, confusion, abnormal speech, irritability, seizures, nystagmus, myoclonic jerks|
|Dehydration or clinical signs of volume depletion||Orthostatic blood pressure changes, tachycardia, oliguria, dry oral mucosa, abnormal skin turgor, dry axillae,|
|Other clinical findings||Weight loss, generalized weakness|